The Oncology Center of the Russian Ministry of Health announced on Sunday the success of the first and second phases of clinical trials for a liver cancer treatment named "Hepatorin-MRNC," which targets primary tumors and cancerous metastases in the liver.
The Chief Oncologist at the Russian Ministry of Health, Andrey Kaprin, stated that the drug is based on albumin microspheres loaded with a radioactive isotope, allowing radiation therapy to be directed toward the tumor, noting the completion of the first and second phases of clinical studies.
